Notre offre FCPI Truffle InnoCroissance 2015 et Mandat de gestion

The fast pace of innovation in IT offers compelling investment opportunities

Truffle Capital is a pioneer investor in the exciting field of Energy

Biotechnology has radically transformed medicine over the past 25 years


Theradiag, previously known as BMD (BioMedical Diagnostics), is a pioneer in the development, manufacturing and commercialisation of high quality and innovative IVD products (in vitro diagnostic). Based on 25 years of experience in this domain, Theradiag is focusing its development strategy on theranostic tests for monitoring biotherapies. Theranostics is an emerging branch of in vitro diagnostic, which aims at giving information in orther to further personalise treatment. Thus,
theranostic tests are associated with a targeted biotherapy so as to foretell or evaluate patient response by measuring one or more bio-markers.

In 2010, Theradiag got the CE mark for and commercialised a new range of products, the Lisa Tracker, aimed at improving monitoring of patients under Anti-TNF treatment.

Truffle Capital board members: Dr. Philippe Pouletty, Antoine Pau